GlassScriptPhysician profile
Marsia Manna
NPI 1164295036
$2,148.82
in general payments reported to CMS, 2019-2025
28 companies · $1,876 in 2025
The $1,876 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $273 · 2025: $1,876.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,148.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $379.05 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $305.82 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $258.58 | 2025 | |
| Novo Nordisk INC | $225.86 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $178.09 | 2024-2025 | Mounjaro, Zepbound, Kisunla |
| Bayer Healthcare Pharmaceuticals INC. | $146.44 | 2024-2025 | |
| Lundbeck LLC | $84.65 | 2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $62.92 | 2025 | Rexulti |
| Exact Sciences Corporation | $58.48 | 2025 | The Cologuard Plus Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $51.94 | 2024-2025 | Trintellix |
| Axsome Therapeutics, INC. | $41.52 | 2025 | Auvelity |
| Corcept Therapeutics | $41.32 | 2024-2025 | Korlym |
| Amgen INC. | $33.66 | 2025 | Evenity |
| Glaxosmithkline, LLC. | $28.22 | 2025 | Trelegy Ellipta, Arexvy |
| Astellas Pharma US INC | $23.57 | 2025 | Veozah |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $22.74 | 2025 | Camzyos |
| Dexcom, INC. | $22.34 | 2025 | Dexcom G6 Transmitter |
| Amneal Pharmaceuticals LLC | $21.77 | 2025 | Unithroid |
| Shield Therapeutics INC | $19.00 | 2025 | |
| Novartis Pharmaceuticals Corporation | $17.66 | 2025 | |
| Vivus LLC | $16.45 | 2024 | Qsymia |
| Sanofi-Aventis U.S. LLC | $16.11 | 2025 | |
| Xeris Pharmaceuticals, INC. | $16.01 | 2025 | Recorlev |
| Evoke Pharma, INC. | $15.92 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.67 | 2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.51 | 2025 | Xifaxan |
| Teva Pharmaceuticals USA, INC. | $14.81 | 2025 | Ajovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.71 | 2025 | Caplyta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marsia Manna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.